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Background: The minor allele of SNP rs3803662 has been shown to correlate with increased breast cancer risk and
with lower expression of TOX3. The SNP is closely located to TOX3 residing within an uncharacterised gene
LOC643714. The aim of the study was to examine the association of the risk allele with expression of TOX3 and
LOC643714, and of mRNA levels and genotype with clinical and pathological characteristics.
Methods: The SNP was genotyped in DNA isolated from blood and normal tissue from 160 breast cancer patients
and mRNA levels were measured by microarrays and quantitative real-time (qRT)-PCR in breast tumours. Association
with clinical and pathological characteristics was analysed by parametric tests.
Results: An association of the risk allele of rs3803662 with lower TOX3 expression was confirmed in oestrogen receptor
(ER) positive tumours. It was more often observed in lobular tumours (p = 0.04), and carriers of the risk allele who had
been diagnosed with luminal A tumours had shorter overall survival (OS) than carriers of the non-risk allele (p = 0.01).
Positive correlation between the mRNA levels of TOX3 and LOC643714 was observed (r = 0.44 and p < 0.001).
Association analysis with tumour pathology showed that low TOX3 and LOC643714 expression correlated with high
Ki67 levels (p = 0.026 and p = 0.002) and the basal subtype (p < 0.001 and p < 0.001), whereas high expression
correlated with ER (p = 0.004 and p < 0.001) and progesterone receptor (PgR) (p = 0.005 and p < 0.001) expression.
Furthermore, high TOX3 and LOC643714 correlated with positive lymph nodes (p < 0.001 and p = 0.01). Patients with
ER positive tumours and high levels of TOX3 mRNA had shorter overall- and distant metastasis free-survival (p = 0.017
and p = 0.021), an effect mostly attributable to patients with luminal B tumours.
Conclusions: The results suggest that the effect of the risk allele of rs3803662 is strongest in luminal A tumours and
that the expression levels of TOX3 and/or LOC643714 affect the progression of breast cancer. The effect may vary
depending on the subtype and developmental stage of the tumour.
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Breast cancer is the most frequent cancer in women
accounting for 23% of all cancers in 2008 [1]. It shows
strong familial aggregation being about twice as com-
mon in first-degree relatives of individuals with the dis-
ease than in the general population [2]. Familial linkage
studies have identified high penetrance, low frequency
mutations in genes such as the breast cancer susceptibil-
ity genes BRCA1 and BRCA2 but these mutations only
account for approximately 20% of the familial risk
(reviewed in [3]). In unselected breast cancer patients,
genome-wide association studies have identified low
penetrance, high frequency SNPs that are associated
with breast cancer risk (reviewed in [4]). SNP rs3803662,
at 16q12, is one of them. It was demonstrated that the
minor allele of rs3803662 conferred increased risk of
breast cancer in European women [5,6], a finding that
has been validated in large studies of unselected patients
and patients with a familial history of breast cancer and
meta-analyses [7-13]. This finding was also observed in
women of East Asian descent [14-16] but not in women
of African American descent [17-19]. The association
was confined to oestrogen receptor positive cancer
[6,20] but studies in large consortia have shown associa-
tions in ER positive and negative breast cancer, albeit
stronger in ER positive disease [21,22]. The minor
rs3803662 allele also increased the risk of breast cancer
in BRCA1 and BRCA2 carriers [21,23,24] as well as in a
population-based study of men [25].
The genes located closest to rs3803662 are TOX3 and
LOC643714. The SNP is in the last exon (exon 4) of
LOC643714 and near the 5’ end of TOX3. The chromo-
somal region spanning the 5’ end of TOX3, the inter-
genic region between TOX3 and LOC643714 and the
entire coding part of LOC643714 are located in a 133 kb
linkage disequilibrium (LD) block [13]. Other SNPs
within this LD block show association with breast cancer
but rs3803662 shows the strongest effect [5,13].
LOC643714 is an uncharacterised gene whose function
is unknown [26]. The TOX3 gene, also known as TNRC9
and CAGF9, has a tri-nucleotide repeat motive [27] and
a high mobility group (HMG)-box [28]. It is involved in
the regulation of calcium dependent transcription and
interacts with cAMP-response-element-binding protein
CREB and CBP (CREB-binding protein) [29]. Addition-
ally, TOX3 can interact with CITED1 and increase tran-
scription [29,30]. CITED1 is a transcription co-regulator
that enhances the activity of transcription factors such
as the ER [31] and SMAD4 [32].
A correlation of the rs3803662 genotype with lower
TOX3 mRNA has been observed in breast tumours
where TOX3 mRNA expression decreased in an allele-
dependent manner [33]. So far, one study showed an ef-
fect of TOX3 expression on breast cancer in thatincreased level of TOX3 mRNA predicted breast cancer
metastasis to bone [34]. In the present study we report
the results of association analysis between the rs3803662
genotype and expression of its closest genes, TOX3 and
LOC643714, in a cohort of breast cancer patients as well
as the correlation analyses between rs3803662, and ex-
pression of TOX3 and LOC643714, with known clinical
and pathological characteristics.
Methods
Tumour and normal tissue samples
Freshly frozen primary breast tumour samples (n = 160)
were obtained from the Department of Pathology at
Landspitali University Hospital, Reykjavik, Iceland as
well as normal tissue samples embedded in paraffin if a
blood sample was not available from the patient. The
patients were diagnosed during the years 1987–2003.
Informed consent was obtained from all participants in
the study. The study was approved by the Icelandic Data
Protection Authority (2001/523 and 2002/463) as well as
the National Bioethics Committee of Iceland (99/051
and 99/051_FS1) and a written consent was obtained
from the participants in the study according to national
guidelines.
DNA isolation and SNP genotyping
DNA isolation from blood samples was performed accord-
ing to Miller et al. [35], and from paraffin-embedded nor-
mal tissue using a xylene treatment followed by proteinase
K digestion and phenol/chloroform/isoamyl alcohol puri-
fication. Taqman assay C_25968567_10 (Applied Biosys-
tems) was used to genotype SNP rs3803662 using 20 ng of
genomic DNA isolated from the blood samples and the
normal tissue. The reaction was carried out in StepOne
Real-Time PCR System (Applied Biosystems). The allele
frequencies of rs3803662 were in Hardy-Weinberg Equi-
librium (p > 0.1).
RNA isolation and quantification
The microarray gene expression data for TOX3 were
retrieved from a study including 359 breast tumours [36]
via GEO (GSE22133 [37]). qRT-PCR was used to confirm
the array data mRNA levels of TOX3 and LOC643714 in
total RNA that was isolated from the identical fresh frozen
breast tumours which were used in the first study. RNA
was isolated using Trizol (Invitrogen) followed by RNeasy
Midi Purification Kit (Qiagen) according to the manufac-
turer protocol. RNA (2 μg) was reverse transcribed with
random hexamer primers using the RevertAid Minus First
strand cDNA synthesis Kit (Fermentas). Quantification of
gene expression was performed with Taqman Gene Ex-
pression Assays (Applied Biosystems) using 1 and 200 ng
cDNA as template for TOX3 (Hs01101330_m1) and





























Figure 1 Patients with luminal A tumours and the risk rs3803662
allele have shorter OS. The OS was compared in patients with
luminal A tumours who were homo- or heterozygous for the risk
rs3803662 allele (CT/TT, n = 20) as opposed to homozygous for the
non-risk rs3803662 allele (CC, n = 26), log rank p = 0.01.
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rounds for LOC643714. The gene expression was calcu-
lated relative to the expression of the reference gene
TATA-binding protein (TBP, 4326322E Applied Biosys-
tems) according to the formula: mRNA expression of
target gene = 2-(mean Ct target – mean Ct reference). Expres-
sion was measured on available RNA samples; 139 and
126 RNA samples for TOX3 and LOC643714, respect-
ively. The level of mRNA expression of LOC643714 was
much lower in all samples tested and in 30 of the 126
samples LOC643714 mRNA was below the range de-
tectable by qRT-PCR. To include these samples in the
association studies the samples were given a Ct value
that was 3.3 cycles higher than the highest LOC643714
Ct value measured. This calculated Ct value was used to
calculate the level of LOC643714 mRNA expression in
the 30 tumours relative to the expression of the refer-
ence gene TBP according to the formula given above.
Clinical information and tumour characteristics
Information regarding the date and cause of death was
obtained from patient records and confirmed by the
Icelandic National Register. The age at diagnosis and in-
formation about tumour size, type and nodal status as
well as ER, progesterone receptor (PgR), ErbB2 and Ki67
levels, was retrieved from records at the Department of
Pathology at the Landspitali-University Hospital. ER,
PgR, ErbB2 and Ki67 levels were evaluated by immuno-
histochemical staining according to the manufacturer’s
protocol (Dako): ER (M7047, clone 1D5, 1:100), PgR
(M3569, clone PgR 636, 1:100), HercepTest (K5207),
and Ki67 (M7240, clone MIB1, 1:100). The ER and PgR
status was determined as being either positive (staining
1+ to 3+) or negative (no staining). The ErbB2 receptor
status was determined as being either positive (3+ stain-
ing plus 2+ staining and positive FISH analysis) or nega-
tive (1+ plus 2+ staining and negative FISH analysis)
[38]. Tumours staining for Ki67 were scored highly pro-
liferative if the number of cells and staining intensity
was above 10% and slowly proliferating below 10%. The
tumours were categorized according to the WHO histo-
logical classification and the histological grade was
determined by the modified Bloom-Richardson system.
The molecular subtypes of the tumours were retrieved
from GEO dataset GSE22133 [37].
Statistical analysis
Pearson’s χ2 analysis was used to test genotype frequencies
for deviations from Hardy-Weinberg equilibrium (HWE)
for SNP rs3803662. Fisher exact test was used to analyse
association between the SNP genotype and clinical and
pathological parameters. The association of the SNP geno-
type and mRNA expression was determined using
ANOVA. The association of mRNA expression, as mea-sured by qRT-PCR, to clinical and pathological parameters
was determined using a t-test or ANOVA. Pearson correl-
ation coefficient was calculated to determine the strength
of the linear relationship between TOX3 and LOC643714
mRNA expression. Analyses of overall survival (OS) and
distant metastasis-free survival (DMFS) were calculated
by using the Kaplan-Meier method and the log-rank test.
All calculations were performed using the statistical pro-
gram R [39] version 2.11.1. Schematic of the analyses and
significant results are depicted for the SNP and mRNA in
Additional file 1: Figures S5 and S6, respectively.
Results
The rs3803662 risk allele is associated with shorter OS
Correlation analysis between the SNP genotypes and clin-
ical and pathological factors of breast cancer was per-
formed. The comparison was made between patients who
were homo- or heterozygous for the risk allele and
patients homozygous for the non-risk allele. We observed
a significant association between the risk allele and lobular
tumours (p = 0.04; Additional file 2: Table S1). An associ-
ation was detected between survival and the risk allele in
the entire cohort. However, when survival was analysed
according to molecular subtypes, patients diagnosed with
luminal A tumours who carried the risk allele had shorter
OS as compared to patients homozygous for the non-risk
allele (p = 0.01, Figure 1). Distant metastasis-free survival
(DMFS) was also shorter in this patient group but the
difference did not reach significance (p = 0.24, Additional
file 1: Figure S1). The rs3803662 genotype did not show
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subtypes.rs3803662 is associated with decreased TOX3 mRNA
expression in ER positive tumours
Gene expression data from microarrays were available
for TOX3 in 160 breast tumours. Expression of TOX3
mRNA was compared to the rs3803662 genotype in the
total set of tumours as well as in ER positive and ER
negative tumours. In ER positive tumours, TOX3 expres-
sion decreased significantly with the number of risk
alleles (p = 0.002, Figure 2). No difference was seen in
ER negative or the entire group of tumours (p = 0.25
and p = 0.29, respectively). To confirm these results,
qRT-PCR was performed to measure TOX3 mRNA
levels in 139 breast tumours available from the micro-
array study. The qRT-PCR results correlated positively
with the microarray results (r = 0.57, p < 0.001) and
showed that the TOX3 mRNA level decreased with the
number of risk alleles in ER positive tumours although
the difference did not reach significance (p = 0.11,
Additional file 1: Figure S2A). As before, no difference
was observed in the ER negative or entire group of
tumours (p = 0.78 and p = 0.53, respectively). Due to
lack of microarray expression data of LOC643714 qRT-
PCR was performed to measure the mRNA levels. There
was correlation between the mRNA levels of TOX3 and
LOC643714 as measured by qRT-PCR (r= 0.45, p < 0.001).





















Figure 2 The minor allele of rs3803662 is associated with
lower TOX3 mRNA expression. Correlation of mRNA expression
level of TOX3 with genotype of rs3803662 in 102 ER positive breast
cancer tumours (p = 0.002). The mRNA levels were measured on
microarrays. ANOVA was used to test for significant difference
between the three genotype groups.decreased with the number of risk alleles in ER positive
tumours but the difference did not reach significance
(p = 0.24, Additional file 1: Figure S2B). The majority
of ER positive tumours are of the molecular subtypes
luminal A and luminal B. Although not significant, a
lower expression of TOX3 and LOC643714 was seen in
tumours with the risk allele in luminal A tumours but
not in luminal B tumours (Additional file 1: Figure S3).
High TOX3 and LOC643714 mRNA correlated with positive
lymph nodes and ER positive tumours
Expression levels of TOX3 and LOC643714 were signifi-
cantly higher in ER positive tumours than in ER negative
tumours (p = 0.004 and p < 0.001, respectively; Table 1).
PgR positive tumours also had significantly higher
TOX3 and LOC643714 mRNA levels than PgR negative
ones (p = 0.005 and p < 0.001, respectively). This was
reflected in different mRNA levels of the two genes
according to molecular subtypes. Luminal A and B
tumours, that are mainly ER positive, expressed signifi-
cantly higher mRNA than ER negative basal tumours
(TOX3 and LOC653714 mRNA vs. subtypes: p < 0.001
and p < 0.001, respectively, Table 1 and Figure 3). Interest-
ingly, two-thirds of the ERBB2 tumours were ER negative,
yet they expressed significantly higher TOX3 mRNA than
basal tumours (p = 0.02, Figure 3). Tumours of patients
who were lymph node positive when diagnosed, had sig-
nificantly higher TOX3 and LOC643714 mRNA levels
than tumours of lymph node negative patients (p < 0.001
and p = 0.04, respectively, Table 1). Tumours with high
expression of Ki67 had significantly lower TOX3 and
LOC643714 mRNA levels than tumours with low expres-
sion of Ki67 (p = 0.026 and p < 0.001, respectively). Fur-
thermore, low mRNA level of LOC643714 associated
with a high histograde (p = 0.01) which likely echoed
the strong correlation of basal tumours with high histo-
grade (data not shown). ErbB2 negative tumours
expressed more LOC643714 mRNA than ErbB2 positive
tumours (p = 0.04), which was not unexpected because the
majority of the ErbB2 negative tumours was ER positive.
Due to the difference in expression of TOX3 and
LOC643714 according to ER status, the association ana-
lysis was performed separately for the ER positive and
negative subgroups. The results of the correlation analyses
in the ER positive subgroup were similar to the whole
group of tumours although in most cases it did not reach
significance, possibly due to lower number of cases
included in the analyses (Additional file 2: Table S2). The
only significant correlation remaining was the one be-
tween high LOC643714 mRNA and low Ki67 (p = 0.02)
and negative ErbB2 status (p = 0.01, Additional file 2:
Table S2). Expression of LOC643714 correlated with that
of TOX3 in ER negative tumours (r = 0.64, p < 0.001) but
not in ER positive tumours (r = 0.13, p = 0.25). The result
Table 1 TOX3 and LOC643714 mRNA expression compared with clinical and pathological characteristics
n TOX3 mRNA p-value n LOC643714 mRNA p-value
139 median (25% and 75%) 126 median (25% and 75%)
Age
< 50 59 (42%) 1.92 (0.9 - 4.5) 0.89 53 (42%) 3.1 E-4 (5.6 E-6 - 1.5 E-2) 0.07
≥ 50 80 (58%) 1.68 (1.1 - 4.0) 73 (58%) 1.7 E-3 (1.1 E-4 - 8.5 E-2)
Tumour size (mm)
≤ 20 42 (31%) 1.5 (1.0 - 4.8) 0.45 39 (31%) 6.4 E-4 (2.7 E-5 - 1.0 E-2) 0.26
> 20 95 (69%) 2.0 (1.0 - 4.5) 85 (69%) 1.1 E-3 (9.2 E-5 - 8.5 E-2)
unknown 2 2
Estrogen receptor
negative 44 (33%) 1.3 (0.4 - 3.3) 0.004 41 (34%) 9.3 E-6 (6.4 E-7 - 5.5 E-4) < 0.001
positive 91 (67%) 2.1 (1.1 - 4.5) 81 (66%) 2.4 E-3 (4.6 E-4 - 9.8 E-2)
unknown 4 4
Progesterone receptor
negative 65 (49%) 1.4 (0.6 - 4.2) 0.005 59 (50%) 1.9 E-4 (1.4 E-6 - 3.1 E-3) < 0.001
positive 67 (51%) 2.1 (1.3 - 4.3) 60 (50%) 3.3 E-3 (4.2 E-4 - 0.5)
unknown 7 7
ErbB2 status
negative 114 (83%) 1.8 (1.0 - 4.2) 0.81 107 (86%) 1.1 E-3 (6.6 E-5 - 7.7 E-2) 0.04
positive 24 (17%) 1.9 (0.8 - 5.0) 18 (14%) 2.7 E-4 (4.7 E-5 - 9.2 E-4)
unknown 1 1
Nodal status
negative 56 (44%) 1.3 (0.4 - 3.4) < 0.001 53 (46%) 5.3 E-4 (1.9 E-6 - 2.3E-2) 0.04
positive 71 (56%) 2.2 (1.2 - 5.3) 62 (54%) 1.4 E-3 (2.0 E-4 - 5.7 E-2)
unknown 12 11
Ki67
Low 97 (71%) 2.1 (1.1 - 4.4) 0.026 87 (70%) 2.4 E-3 (2.2 E-4 - 9.0 E-2) < 0.001
High 39 (29%) 1.2 (0.7 - 2.4) 37 (30%) 9.6 E-5 (1.9 E-6 - 9.0 E-4)
unknown 3 2
Histograde
1 12 (9%) 1.6 (0.8 - 3.5) 0.16 12 (9%) 1.1 E-3 (2.7 E-4 - 3.5 E-2) 0.01
2 78 (57%) 1.9 (1.1 - 4.4) 69 (56%) 3.5 E-3 (1.9 E-4 - 9.8 E-2)
3 47 (34%) 1.6 (0.5 - 4.2) 43 (35%) 2.3 E-4 (3.3 E-6 - 1.5 E-3)
unknown 2 2
Familial status 1
BRCA2 26 (19%) 2.9 (0.8 - 5.1) 0.90 25 (20%) 6.7 E-4 (1.2 E-4 - 4.2 E-3) 0.40
Non-BRCA2 112 (81%) 1.6 (1.0 - 4.2) 100 (80%) 1.2 E-3 (6.3 E-5 - 6.4 E-2)
unknown 1 1
Subtype
Basal 20 (17%) 0.5 (0.1 – 1.3) < 0.001 23 (21%) 3.1 E-6 (2.3 E-7 - 2.0 E-4) < 0.001
ERBB2 15 (12%) 1.6 (1.2 - 5.0) 9 (8%) 9.7 E-4 (2.7 E-4 - 1.5 E-2)
Luminal A 43 (36%) 1.6 (1.1 - 3.1) 38 (35%) 8.9 E-3 (5.0 E-4 - 9.8 E-2)
Luminal B 30 (25%) 4.0 (1.6 - 5.4) 28 (26%) 1.2 E-3 (6.7 E-4 – 3.0 E-1)
Normal-like 12 (10%) 1.8 (1.2 - 4.4) 10 (9%) 5.8 E-4 (3.4 E-5 - 2.7 E-3)
Unclass/unknown 19 18
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Table 1 TOX3 and LOC643714 mRNA expression compared with clinical and pathological characteristics (Continued)
Histological type
Ductal 116 (86%) 2.1 (1.0 - 4.5) 0.12 105 (86%) 1.1 E-3 (9.2 E-5 - 5.2 E-2) 0.91
Lobular 11 (8%) 1.3 (1.3 - 2.2) 9 (7%) 6.2 E-4 (1.2 E-4 - 7.8 E-3)
other 8 (6%) 1.0 (0.6 - 1.5) 8 (7%) 9.8 E-5 (5.2 E-6 - 2.2 E-2)
unknown 4 4
Metastasis
negative 63 (50%) 1.6 (0.9 - 3.1) 0.18 63 (55%) 6.4 E-4 (6.3 E-6 - 1.9 E-2) 0.16
positive 63 (50%) 1.9 (1.1 - 4.9) 52 (45%) 1.6 E-3 (1.4 E-4 - 8.1 E-2)
unknown 13 11
The table shows the median and the 25th and 75th percentiles. The p-value is calculated with log2 transformed data using a t-test or ANOVA.
1 One tumour sample was BRCA1 positive and was not used in familial status calculations.
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the whole group of tumours in that high TOX3 and
LOC643714 mRNA levels were associated with positive
lymph nodes (p < 0.001 and p = 0.01, respectively) and
a positive PgR status, although only significant for
TOX3 (p = 0.002, Additional file 2: Table S3). But there
was lack of correlation between low mRNA levels of
TOX3 and LOC643714 and high expression of Ki67 and
low mRNA level of LOC643714 and negative ErbB2 status
of the tumour as well as high histograde. A significant cor-
relation was observed between high TOX3 mRNA in
tumours of patients with metastasis (p = 0.015, Additional
file 2: Table S3), which was observed as a trend in the
whole group of tumours (Table 1).Elevated TOX3 mRNA expression in breast tumours is
associated with poor survival
Survival was compared between patients with tumours
that expressed high mRNA levels (above average) of TOX3
or LOC643714 as opposed to low levels (below average).
Patients with tumours that express high TOX3 mRNA had
shorter DMFS and OS (p = 0.015 and p = 0.022, re-
spectively, Figure 4). This effect was independent of
lymph node status. Survival analysis within subgroups
depending on ER status revealed that high TOX3
mRNA expression in patients with ER positive tumours
resulted in shorter DMFS and OS than in patients with
low TOX3 mRNA (p = 0.029 and p = 0.017, respect-
ively, Figure 4). This effect was mostly due to tumours
of the luminal B subtype because their removal from
the analysis resulted in loss of the effect of TOX3 mRNA
on OS and DMFS (log rank p = 0.64 and log rank p = 0.86,
respectively) whereas removal of luminal A tumours had
small effect on survival (OS: log rank p = 0.02 and DMFS:
log rank p = 0.05; Additional file 1: Figure S4). Fewer
tumours are within the ER negative group and the effect of
TOX3 mRNA level on survival was not statistically signifi-
cant. There was no effect of high LOC643714 mRNA on
DMFS or OS.Discussion
In summary, the minor allele of SNP rs3803662 was
associated with shorter survival in breast cancer patients
with luminal A tumours, with lower mRNA expression of
TOX3 in ER positive tumours as well as being more fre-
quently observed in lobular tumours (Additional file 1:
Figure S5). Also, low expression of TOX3 and the
neighbouring gene LOC643714 was associated with high
Ki67 and the basal tumour subtype while high mRNA ex-
pression was associated with ER status, positive lymph
nodes at diagnosis and shorter survival (Additional file 1:
Figure S6).
The risk allele of rs3803662 has been shown to associ-
ate with ER and PgR status [6,11,20-22,40], grade of
tumours [21,22,40] and diagnosis before the age of 60
[9]. In our study cohort, that was smaller than the afore-
mentioned studies, we did not observe a correlation be-
tween genotype at rs3803662 and age or tumour
characteristics except that the risk allele was more fre-
quent in patients with lobular tumours, which is in
agreement with published data [6,21]. The Breast Cancer
Association Consortium (BCAC) recently reported that
ER positive patients, homozygous for the risk allele, had
poorer overall and breast cancer specific survival than
patients, homo- and heterozygous for the non-risk allele
[40]. The BCAC study did not include information on
the molecular subtypes of the tumours. In our cohort,
the risk allele was significantly associated with poor
overall survival only in patients with luminal A tumours.
The rs3803662 genotype has been shown to associate
most strongly with the ER/PgR positive and ERBB2
negative subgroups [21], which is the expression pattern
of tumours of the luminal A subtype, further supporting
that the effect seen in the BCAC study may be con-
nected to luminal A tumours.
A decrease in TOX3 mRNA according to the rs3803662
genotype was observed in a large Dutch study of 1401
breast tumours [33] but analysis according to ER status
was not reported. In our study, the allele-dependent de-






















































Figure 3 TOX3 and LOC643714 mRNA expression was lowest in tumours of the basal subtype. The mRNA expression levels in: A) TOX3
(p < 0.001) and B) LOC643714 (p < 0.001) in five breast tumour subtypes. ANOVA was used to test for differences in expression between the
different subtypes. The difference in TOX3 expression between basal and ERBB2 tumours was significant (p = 0.02).
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were quantified by microarrays and confirmed by qRT-
PCR. A significant association was not seen using the latter
method, possibly due to the lower number of tumours that




























































Figure 4 High TOX3 mRNA was associated with shorter survival. Tumo
mRNA levels that were above or below average, respectively. Accordingly,
46 high, log rank p = 0.022; B) DMFS: 83 low vs. 43 high, log rank p = 0.01
p = 0.017; D) DMFS: 49 low vs. 33 high, log rank p = 0.029.was only measured by qRT-PCR and a positive correl-
ation was found between TOX3 and LOC643714 mRNA
levels. The closely located genes are potentially co-regu-
lated. LOC643714 mRNA expression in breast tumours














































































urs were classified into high and low expressing tumours based on
survival was analysed in the whole group of patients: A) OS: 88 low vs.
5 and in ER positive patients: C) OS: 53 low vs. 35 high, log rank
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reported negligible mRNA levels of LOC643714 in nor-
mal breast and breast tumours [13]. A larger cohort
will be necessary to confirm the association between
rs3803662 and LOC643714 expression.
The rs3803662 genotype may only affect expression of
TOX3 and LOC643714 in certain tumour subtypes. Al-
though we observed a reduction in gene expression in ER
positive tumours, our preliminary analysis suggests that
this is limited to luminal A tumours (Additional file 1:
Figure S3) and another mechanism may be responsible for
controlling expression of these genes in luminal B
tumours. Although a higher number of tumours are
required to confirm this observation, the majority of the
adverse effect of high TOX3 expression in ER positive
tumours was related to luminal B tumours (Additional file
1: Figure S4). Furthermore, higher TOX3 mRNA was
observed in patients with luminal B tumours with metas-
tasis (p = 0.056, data not shown) but more tumours are
necessary to observe a significant association of metastasis
to bone as has been reported with high TOX3 expression
[34]. The risk allele of rs3803662 was highly correlated
with a subgroup of basal tumours that expresses EGFR
and CK5/6 but not ER, PgR and ERBB2 [40]. Expression
of TOX3 and LOC643714 was significantly lower in basal
tumours in our cohort but we did not observe differences
in expression according to genotype or a difference in al-
lele distribution compared to the other tumour subtypes
as has been reported for rs9940048, which is located
within TOX3 [41].
The rs3803662 SNP may regulate expression of genes
more distantly located than TOX3 and LOC643714. It
lies within an evolutionary conserved region that has an
open chromatin conformation suggestive of an active
transcription regulatory region [13]. Our preliminary
analysis of the association of the rs3803662 risk allele
with the expression of genes located within 1 Mb of the
SNP revealed an association with the retinoblastoma-like
2 gene (RBL2) only, where an increase in expression was
seen with the number of risk alleles (p = 0.02, data not
shown). This result is in agreement with Udler et al.,
who reported a dose-dependent association between the
rs3803662 risk allele with increased expression of RBL2
mRNA expression in lymphocytes; however, an associ-
ation between the rs3803662 genotype and RBL2 mRNA
expression in 77 breast tumours was not seen [13]. Ex-
pression of RBL2 was recently reported to be associated
with prognosis [40]. It is a member of the retinoblast-
oma gene family [42] and has been shown to be involved
in cell cycle regulation, and it is frequently deleted in
breast tumours [43].
Very low expression of TOX3 and LOC643714 was
observed in the basal subtype, an observation that has been
reported for TOX3 [41]. The significantly lower TOX3 andLOC643714 expression in tumours expressing high Ki67
was due to the relatively high number of basal tumours
expressing high Ki67. Expression correlated significantly
with metastasis in ER negative tumours but not with me-
tastasis to bone [34]. High expression of both TOX3 and
LOC643714 mRNA was observed in tumours of lymph
node positive patients but only TOX3 mRNA correlated
with survival where high levels were seen in patients with
shorter overall and distant metastasis free survival in the
entire group and for patients with ER positive tumours.
This discrepancy between TOX3 and LOC643714 may pos-
sibly be due to fewer LOC643714 tumours than for TOX3,
different distribution of available samples into subtypes, or
the fact that there was not a correlation between TOX3
and LOC643714 in ER positive tumours. It was recently
reported that TOX3 expression was not associated with
prognosis [40]. The study was large but the data came from
9 separate studies in publicly available databases. Thus, we
suggest that the effect potentially vanished due to variabil-
ity in study design and data acquisition.
The biological mechanism that potentially explains our
results is the implication of TOX3 in proliferation and
apoptosis. Knockdown of TOX3 expression with siRNA in
the luminal A breast cancer cell line ZR-75-1 increased
cellular proliferation [44]. The same study described a
FOXA1 binding site at breast cancer SNP rs4784227,
whose risk allele segregates with the risk allele of
rs3803662; FOXA1 preferentially bound the site that
included the rs4784227 risk allele resulting in a 5-fold de-
crease in TOX3 expression [44]. Therefore, the correlation
of FOXA1 expression with luminal A tumours [45] could
explain lower expression of TOX3 in our study and poorer
survival of carriers of the rs3803662 risk allele and luminal
A tumours. In these tumours, TOX3 would appear to be a
tumour suppressor. However, a different scenario has
been described in neuronal cells that potentially may ex-
plain the effect of high TOX3 mRNA in ER positive
tumours which we ascribe to luminal B tumours.
Increased expression of TOX3 protected neuronal cells
from cell death by altering expression levels of genes that
affect apoptosis [30]. Such function in ER positive breast
cancer cells, where TOX3 expression is high, could pro-
mote tumour enlargement, invasion of nearby tissues,
seeding of lymph nodes which would subsequently
shorten the time until death or distant metastasis. The ef-
fect of TOX3 on apoptosis in neuronal cells was mediated
via its interaction with CITED1 and ERE [30] and may be
the case for proliferation as well. However, the TOX3
ERE-mediated transcription appeared independent of ER
and oestrogen [30] unlike that of CITED1, a co-activator
of ER that modulates ER responsive genes [31]. We can
only speculate that LOC643714 has a role in tumour de-
velopment based on results similar to TOX3 but its
mRNA is not translated and its function is unknown.
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http://www.biomedcentral.com/1471-2407/12/621Although we assume that mRNA expression of our can-
didate genes may differently affect breast tumour sub-
types, the study is small and the analyses according to ER
status or molecular subtypes further reduced the number
of tumours. As such, the study is exploratory and the
results should be confirmed with a larger number of
tumours. Our findings provide a suitable basis for further
validation studies.
Conclusions
Taken together, the data suggest that the rs3803662 geno-
type may affect expression of TOX3 and LOC643714 in
tumours that originate in some developmental structures
within the breast, such as the lobes, and in different mo-
lecular subtypes of tumours, such as luminal A and pos-
sibly in subgroups of basal tumours. Furthermore, in
other types of breast cancer, possibly luminal B tumours,
expression of these genes may be controlled by other
mechanisms where high expression has adverse effects on
prognosis. Although further analysis is needed, we con-
clude that genotype at rs3803662 and expression of TOX3
and LOC643714 have adverse effect on breast cancer
prognosis.
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